Dealing with Calcification in BTK Arteries: Is Lithoplasty the Answer?

Similar documents
Shockwave Medical Lithoplasty. Thomas Zeller MD Universitäts-Herzzentrum Freiburg & Bad Krozingen, Germany

The Role of Lithotripsy in Solving the Challenges of Vascular Calcium. Thomas Zeller, MD

Shockwave Intravascular Lithotripsy System treatment of calcified lesions: Intravascular OCT analysis

Safety and Feasibility of Intravascular Lithotripsy for Treatment of Common Femoral Artery Stenoses

DISRUPT PAD. (( Data Summary )) DISRUPT PAD Data Summary SPL Rev. B 2016 Shockwave Medical Inc. All rights reserved.

Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria

DISRUPT CAD. Todd J. Brinton, MD Clinical Associate Professor of Medicine Adjunct Professor of Bioengineering Stanford University

Final Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)

Final Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)

Klinikum Rosenheim Department of Diagnostic and Interventional Radiology

Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort

Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry

Fabrizio Fanelli, MD, EBIR Director Vascular and Interventional Radiology Department "Careggi " University Hospital Florence - Italy

Intravascular Imaging Insights into the Mechanism of Action of Focal Force Balloon Angioplasty

Future Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit?

ISR-treatment The Leipzig experience with purely mechanical debulking. Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany

BTK Intervention with Drug- Coated Balloons: Past Lessons and Future Exploration

One Year after In.Pact Deep: Lessons learned from a failed trial. Prof. Dr. Thomas Zeller

Update from Korea on the Lutonix SFA registry 12 month data

Atherectomy: Jetstream and Directional. George S. Chrysant, M.D.

The present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio

ILLUMENATE FIH Direct DCB Cohort 12-Month Results

Excimer Laser angioplasty for femoro-popliteal disease. Sendai Kousei Hospital, Tokyo Kamata Hospital Naoto Inoue MD, FSCAI, FJCC, FAHA

The Crack and Pave technique for highly resistant calcified lesions. Manuela Matschuck MD University Hospital Leipzig Department Angiology

TOBA II 12-Month Results Tack Optimized Balloon Angioplasty

BIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort

Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)

The Utility of Atherectomy and the Jetstream Atherectomy System

12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort. Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany

Hiroshi Ando, MD Kasukabe Chuo General Hospital Saitama, Japan

LIBERTY 360 Study. 15-Jun-2018 Data 1. Olinic Dm, et al. Int Angiol. 2018;37:

Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD

CLI Treatment Using Long and Scoring Balloons

Endovascular Intervention BtK Intervention in Patients with Chronic Dialysis

Long Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA

The essentials for BTK procedures: wires, balloons, what else

Drug-coated balloons in BTK:

DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes

Aggressive BTK Revascularization and Advanced Wound Care - Patient Specific Therapy Concepts

PATIENT SPECIFIC STRATEGIES IN CRITICAL LIMB ISCHEMIA. Dr. Manar Trab Consultant Vascular Surgeon European Vascular Clinic DMCC Dubai, UAE

First time data release: Initial experience with the temporary Spur Stent System: DEEPER Trial first-in-man results Jihad A. Mustapha, MD, FACC,

Koen Keirse, MD RZ Tienen, Belgium

MICHAEL R. JAFF, DO MASSACHUSETTS, UNITED STATES. Medtronic Further. Together

Maximizing Outcomes in a complex population with Drug-coated balloon

DCB in my practice: How the evidence influences my strategy. Yang-Jin Park

TOBA Trial 12 months Results

SFA CTO Lesion Management laser or directional atherectomy?

The LIMBO trial: a RCT investigating adventitial dexamethasone infusion to prevent restenosis in BTK arteries utilizing a novel angiographic endpoint

Disclosures. Tips and Tricks for Tibial Intervention. Tibial intervention overview

Atherectomy is Still Live and Effective. John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center UC Davis Health System

Comparison of Angiographic Dissection Patterns Caused by Long vs Short Balloons During Balloon Angioplasty for Chronic Femoropopliteal Occlusions

How do I use mechanical debulking for the treatment of arterial occlusions

Bioabsorbable Scaffolding: Technology and Clinical Update. PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland

Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease?

Study of a Balloon-Expandable Covered Stent for Obstructive Lesions in the Iliac Artery

Update on the OPTIMIZE BTK Trial. Marianne Brodmann, MD Division of Angiology Medical University Graz, Austria

OCT Guided Atherectomy: Initial Results of the VISION Trial Using the Pantheris Catheter. Patrick Muck, MD

Atherectomy with thrombectomy of. Rotarex S : The Leipzig experience

Patterns of Vessel Calcification and Clinical Relevance

The latest evidences from the DES trials in peripheral arterial disease

2-YEAR DATA SUPERA POPLITEAL REAL WORLD

PRISM Trial. Retrospective Case Review of Technical Success Using the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery

IN.PACT AV Access IDE Study Full Baseline Data. Robert Lookstein, MD MHCDL New York, NY On Behalf of the IN.PACT AV ACCESS Investigators

Initial Clinical Experience with a Novel Dedicated Cobalt Chromium Stent for the Treatment of Below-the-knee Arterial Disease

Objective assessment of CLI patients Hemodynamic parameters

Present & future of below the knee stenting

IMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the on-label use of

Lessons learnt from DES in the SFA is there any ideal concept so far?

Long-term Zilver PTX Data from Japan: 5-year Results in the Real World

Vessel Preparation: What does it mean and what are the current tools? Lawrence Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA

Calcium Removal and Plaque Modification in the Era of DEB and Contemporary Stenting for Femoro- Popliteal Disease

RAPID Phase III Perspectives from the Medical Device Industry

Is there still any space left for DES in the BTK area??? (Angiolite BTK trial, 6 month Data)

Angiographic dissection pattern and patency outcomes of post balloon angioplasty for SFA lesions -a retrospective multi center analysis-

Lessons & Perspectives: What is the role of Cryoplasty in SFA Intervention?

Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD

The Freeway Stent Study: the 12 Months results highly favor the use of DEB in combination with stenting

Making BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD

LUTONIX DCB in BTK Update on the BTK clinical program & single center experience

The clinical outcome camparison between covered stent(cv) and drug-eluting balloon(deb) for SFA lesions: a single center result

Technical Aspects for Treating AV Dialysis Fistulae with the IN.PACT DCB. Andrew Holden Auckland Hospital Auckland, New Zealand

Nicolas W Shammas, MD, MS

Balloon Expandable Covered Stents. Suddenly a Crowded Space

2 Year Results from the MDT SFA Japan Trial - DCB vs. standard PTA for the treatment of atherosclerotic lesions in the SFA/PPA

Lutonix DCB in BTK Update on the BTK real world registry and RCT

COVERA covered stent to treat stenosis in arteriovenous fistula: 6-month results from the prospective, multi-center, randomized AVeNEW study

The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions

William A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, PA USA

Christian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide

Latest Insights from the LEVANT II study and sub-group analysis

Calcified lesions optimal treatment

Specificities for infrapopliteal stents

Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 24-Month Results

Wifi classification does not predict limb amputation risk in dialysis patients following critical limb ischemia revascularization

Disclosures. Talking Points. An initial strategy of open bypass is better for some CLI patients, and we can define who they are

Importance of Thorough Vessel Preparation Followed By Anti- Restenotic Therapy: An Update from the DEFINITIVE AR Study

Endovascular Options in Critical Limb Ischemia: Below The Knee Therapies

Why and how to prep the vessel

Use of Laser In BTK Disease (CLI)

January 23, Vascular and oncological interventional radiology Paris Descartes University

Transcription:

Dealing with Calcification in BTK Arteries: Is Lithoplasty the Answer? Andrew Holden, MBChB, FRANZCR, EBIR Director of Interventional Radiology Auckland, New Zealand LINC 2017 January 25 th 2017

Disclosure Speaker name: Andrew Holden I have the following potential conflicts of interest to report: X Consulting Clinical Investigator for Shockwave Medical Employment in industry Stockholder of a healthcare company Owner of a healthcare company Other(s) I do not have any potential conflict of interest

Calcification in BTK Arteries Seen in many CLI patients but especially in diabetics, elderly and dialysis-dependent patients Occurs in both intimal and medial layers (often mixed) Higher prevalence of medial calcification in tibial arteries than other locations Medial Calcification Intimal Calcification Images Courtesy J Mustapha

Calcification in BTK Arteries Risks of angioplasty with calcified stenotic disease residual stenosis, dissection, perforation, restenosis and reduced drug absorption Calcified lesions in CLI patients 1.5 X increased mortality, 5 X amputation rate! 1,2 100% 100% 100% 100% 90% 90% 87.5% 1.0 0.9 0.8 75% 50% 0.59 0.7 0.72 0.75 0.68 0.6 0.66 0.5 0.52 50% 50% 0.4 0.45 0.46 0.3 25% Primary Patency LLL 0.2 0.1 0% 0.0 1a 1b 2a 2b 3a 3b 4a 4b Calcium distribution evaluation by CTA (circumferentially) and DSA (longitudinally) 1. Fanelli et al. Calcium Burden Assessment and Impact on Drug-Eluting Balloons in Peripheral Arterial Disease. Cardiovasc Intervent Radiol (2014) 37: 898-907. Perforation after angioplasty 1. J Am Cardiol 2008;51(20):1967-74 2. Huang CL et al, PLoS ONE 9(2): e9020

Lithoplasty Lesion modification using localized lithotripsy in a balloon Tissue-selective: Hard on hard tissue, Soft on soft tissue Lithotripsy waves travel outside balloon Designed to disrupt both superficial, deep calcium Designed to normalize vessel wall compliance prior to controlled, low pressure dilatation Effective lesion expansion with minimized impact to healthy tissue Familiar Balloon-based endovascular technique Front-line balloon strategy (.014 compatible)

Lithoplasty

Lithoplasty in Femoropopliteal Arteries DISRUPT PAD I 35 subjects, 3 sites Jan 2014 Sep 2014 DISRUPT PAD II 60 subjects, 8 sites Jun 2015 Dec 2015 High procedural success Stand alone treatment in the vast majority of cases Excellent safety profile Sustained patency and clinical benefit, at least to 6 months

Lithoplasty in Femoropopliteal Arteries DISRUPT PAD I 35 subjects, 3 sites Jan 2014 Sep 2014 DISRUPT PAD II 60 subjects, 8 sites Jun 2015 Dec 2015 High procedural success Stand alone treatment in the vast majority of cases Excellent safety profile Sustained patency and clinical benefit, at least to 6 months Safety and Feasibility of the Shockwave Medical Lithoplasty System for the Treatment of BTK Arterial Stenoses

Lithoplasty in BTK Arteries: Study Design Safety and Feasibility of Lithoplasty in calcified, stenotic Infrapopliteal Arteries Device: 2.5 to 3.5 X 60 mm Lithoplasty 20 patients treated at 5 sites Population: RC 1 5 infrapopliteal disease. Target lesion: 2.5 3.5 mm, >50% stenosis, < 150 mm length, single/multiple targets allowed Safety Major Adverse Events at 30 day including death, MI, revascularization and amputation Effectiveness - % reduction in diameter stenosis

Baseline and Procedural Characteristics Baseline N= 8 Age 79 Male gender 87.5% (7) Diabetes 25.0% (2) Hypertension 100% (8) Hyperlipidemia 100% (8) Renal disease 25.0% (2) Current Smoker 0.0% (0) Rutherford Class -- RC 3 37.5% (3) RC 4 0.0% (0) RC 5 62.5% (5) Procedure N= 8 Procedure time (min) 64 Fluoroscopy time (min) 12.7 Contrast (cc) 97.4 Target lesion -- TP Trunk 12.5% (1) Anterior tibial 62.5% (5) Posterior tibial 12.5% (1) Peroneal 12.5% (1) Pre-dilatation 12.5% (1) Lithoplasty balloons (N) 1.4 Number pulses 40 Mean Pressure (mmhg) 6 Stents 0.0% (0)

Baseline and Procedural Characteristics Baseline N= 8 Age 79 Male gender 87.5% (7) Diabetes 25.0% (2) Hypertension 100% (8) Hyperlipidemia 100% (8) Renal disease 25.0% (2) Current Smoker 0.0% (0) Rutherford Class -- RC 3 37.5% (3) RC 4 0.0% (0) RC 5 62.5% (5) Procedure N= 8 Procedure time (min) 64 Fluoroscopy time (min) 12.7 Contrast (cc) 97.4 Target lesion -- TP Trunk 12.5% (1) Anterior tibial 62.5% (5) Posterior tibial 12.5% (1) Peroneal 12.5% (1) Pre-dilatation 12.5% (1) Lithoplasty balloons (N) 1.4 Number pulses 40 Mean Pressure (mmhg) 6 Stents 0.0% (0)

Interim Angiographic and Safety Results Angiographic core lab adjudicated Pre N= 8 lesions Post N= 8 lesions MLD (mm) 1.2 2.5 % diameter stenosis (DS) 61.7% 21.2% % DS reduction -- 65.0% Pre-Procedure N=8 lesions RVD (mm) 3.1 Lesion length (mm) 38.0 Calcified length (mm) 52.2 Calcification -- Moderate 87.5% (7) Severe 12.5% (1) Post-Procedure N=8 lesions Acute gain (mm) 1.3 Thrombus 0% (0) Abrupt closure 0% (0) No reflow 0% (0) Distal embolization 0% (0) Dissections 0% (0) Perforations 0% (0)

Interim Angiographic and Safety Results Angiographic core lab adjudicated Pre N= 8 lesions Post N= 8 lesions MLD (mm) 1.2 2.5 % diameter stenosis (DS) 61.7% 21.2% % DS reduction -- 65.0% Pre-Procedure N=8 lesions RVD (mm) 3.1 Lesion length (mm) 38.0 Calcified length (mm) 52.2 Calcification -- Moderate 87.5% (7) Severe 12.5% (1) Post-Procedure N=8 lesions Acute gain (mm) 1.3 Thrombus 0% (0) Abrupt closure 0% (0) No reflow 0% (0) Distal embolization 0% (0) Dissections 0% (0) Perforations 0% (0) No MAE including death, MI, target limb revascularization and amputation reported to date

Recorded Case 8 th November 2016 76 year old male Rest pain left foot Pre-tibial non-healing ulcer

Recorded Case 8 th November 2016

Recorded Case 8 th November 2016

Recorded Case 8 th November 2016 Inflation to 4 ATM

Recorded Case 8 th November 2016 Lithoplasty @ 4 ATM

Recorded Case 8 th November 2016

Recorded Case 8 th November 2016 Inflation to 4 ATM Lithoplasty @ 4 ATM

Recorded Case 8 th November 2016

Recorded Case 8 th November 2016

Recorded Case 8 th November 2016

Recorded Case 8 th November 2016

Conclusions Endovascular outcomes in BTK treatment are poor despite the multiple therapies currently available Calcium is a challenge in endovascular treatment and found in both intimal and medial layers Lithoplasty is designed to treat both superficial and deep calcium allowing vessel expansion without angiographic complications Early results of Lithoplasty in BTK lesions show consistent reduction in stenosis and no procedural complications, including distal embolization

Dealing with Calcification in BTK Arteries: Is Lithoplasty the Answer? Andrew Holden, MBChB, FRANZCR, EBIR Director of Interventional Radiology Auckland, New Zealand LINC 2017 January 25 th 2017